# A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

> **NCT04809818** · PHASE1 · COMPLETED · sponsor: **Lumosa Therapeutics Co., Ltd.** · enrollment: 65 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** LT3001 drug product
- **DRUG:** Placebo
- **DRUG:** Aspirin
- **DRUG:** Clopidogrel
- **DRUG:** Apixaban
- **DRUG:** Dabigatran

## Key facts

- **NCT ID:** NCT04809818
- **Lead sponsor:** Lumosa Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-21
- **Primary completion:** 2021-08-05
- **Final completion:** 2021-08-05
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809818, "A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04809818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*